DATE10 Jul

NIFTY 24,207 ▲ 1.02%BANK NIFTY 58,046 ▲ 1.39%NIFTY IT 28,010 ▲ 1.96%NIFTY PHARMA 25,674 ▲ 0.07%GODREJIND 1,418 ▲ 16.28%J&KBANK 193 ▲ 14.39%ZENSARTECH 508 ▲ 13.60%INDIANB 871 ▲ 9.78%NEWGEN 517 ▲ 9.30%BLUEJET 624 ▲ 8.62%MRPL 162 ▲ 8.56%BRIGADE 575 ▲ 7.60%KALYANKJIL 476 ▲ 7.48%FSL 260 ▲ 6.90%NIFTY 24,207 ▲ 1.02%BANK NIFTY 58,046 ▲ 1.39%NIFTY IT 28,010 ▲ 1.96%NIFTY PHARMA 25,674 ▲ 0.07%GODREJIND 1,418 ▲ 16.28%J&KBANK 193 ▲ 14.39%ZENSARTECH 508 ▲ 13.60%INDIANB 871 ▲ 9.78%NEWGEN 517 ▲ 9.30%BLUEJET 624 ▲ 8.62%MRPL 162 ▲ 8.56%BRIGADE 575 ▲ 7.60%KALYANKJIL 476 ▲ 7.48%FSL 260 ▲ 6.90%

Morning brief · Saturday, 11 July 2026

Nippon India MF makes a ₹2,726 crore bet on Max Financial

Market pulse

Indian markets surged higher, with IT and banking stocks leading the Nifty 50 to a close well above the 24,200 mark. While the pharmaceutical sector remained flat, individual names like Godrej Industries, J&K Bank, and Zensar Technologies posted double digit gains.

From the investor's mind

One post worth your time, explained

@unseenvalue · on X

Sajal Kapoor, a prominent investor, has highlighted that while Biocon exhibits strong scientific capabilities, its financial performance, particularly its Return on Capital Employed (ROCE), has been a concern for shareholders. He emphasizes that for a listed company, a consistent ROCE of over 20% is crucial for incremental capital deployment, a metric where Biocon has historically underperformed. According to Kapoor, despite Biocon's excellent science, its shareholder economics are poor due to this lagging ROCE.

Yesterday's big moves